Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in Leukemia
NCT06898983Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by The First Affiliated Hospital of USTC. Started Jul 2025; status: recruiting.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT06898983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06898983.